CSF, MRI, and PET biomarkers of neuroinflammation in Alzheimer's disease

阿尔茨海默病神经炎症的 CSF、MRI 和 PET 生物标志物

• 批准号: 9194839
• 负责人: William Tzu-lung Hu
• 金额: $ 77.03万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-08-15 至 2021-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9194839
• 关键词: Accounting; Acute; Algorithms; Alzheimer' s Disease; Anti-Inflammatory Agents; Anti-inflammatory; Biochemical; Bioinformatics; Biological Assay; Biological Markers; Blood - brain barrier anatomy; Blood Vessels; Brain; Brain imaging; CD4 Positive T Lymphocytes; Cells; Cerebrospinal Fluid; Cessation of life; Chronic; Clinical Trials; Cognitive; Cognitive deficits; Complement; Complement Activation; Complement Suppression; Data; Dementia; Development; Diagnosis; Encephalitis; Event; FDA approved; Fractalkine; Future; Helper-Inducer T-Lymphocyte; Human; Image; Image Analysis; Immune system; Immunophenotyping; Impaired cognition; Individual; Inflammation; Inflammatory; Interleukin-10; Interleukin-7; Iron; Label; Life; Ligands; Link; Liquid substance; MRI Scans; Machine Learning; Magnetic Resonance Imaging; Measurement; Measures; Mediating; Methods; Modality; Neurodegenerative Disorders; Outcome; Pathogenesis; Pathology; Pathway Analysis; Pathway interactions; Patients; Pattern; Pattern Recognition; Peptides; Peripheral; Phagocytes; Pharmaceutical Preparations; Phenotype; Population; Positron-Emission Tomography; Process; Proteins; Regulation; Role; Specificity; Staging; Symptoms; System; T-Cell Activation; T-Lymphocyte; Testing; Th1 Cells; Therapeutic; Tracer; base; biomarker panel; brain dysfunction; cell type; chemokine; cohort; cytokine; demographics; genetic variant; imaging biomarker; inflammatory marker; insight; iron oxide; macrophage; migration; mild cognitive impairment; molecular imaging; neuroinflammation; neuropathology; neuroprotection; novel

ABSTRACT Alzheimer’s disease (AD) is the most common form of neurodegenerative disorder. Inflammatory changes in the brain are thought to represent key processes in the onset and progression of AD, but it remains unclear whether neuroinflammation confers neuroprotection, accelerated degeneration, or possibly both. Such an understanding in living humans is critical if we are to begin clinical trials using the array of FDA-approved immunomodulatory drugs in the future. We propose that complement- mediated neuroinflammation is protective in the early AD stages, while suppression of complement activities is accompanied by the development of greater cognitive deficits and faster cognitive decline. Our preliminary data from multiple cohorts support this hypothesis by showing 1) reduced levels of cerebrospinal fluid (CSF) complement-related markers occur in the dementia stage but not mild cognitive impairment (MCI) stage of AD; 2) reduced CSF complement-related markers and elevated CSF interleukin-10 (IL-10) levels are associated with faster decline in AD; and 3) CSF inflammatory protein alterations reveal networks of cellular and protein regulations. In the In the current application, we will build on the association between complement related proteins and rates of cognitive decline in AD to identify associated changes in soluble CSF cytokines and chemokines, differential inflammatory cell type regulation, and imaging correlates of neuroinflammation. This application takes advantage of our group’s strengths in performing CSF cytokine measurements, CSF immunophenotyping, molecular imaging of neuroinflammation through positron emission tomography (PET) and iron-enhanced MRI, and network analysis through a novel biochemical-bioinformatics pipeline. We will directly identify individual and networks of soluble CSF cytokines that accompany the transition from the MCI to the dementia stage of AD, correlate the complement and other altered pathways with microglial activation through two modern PET tracers (11C-PBR28 and 18F-FEPPA), and measure changes in individual T helper cell (type 1, 2, 17) and non-T cell populations. This application represents the first attempt to correlate, at the individual level and at the group level, CSF and imaging measures of neuroinflammation. If successful, this application will advance the understanding of neuroinflammation in AD through parallel approaches, form the basis of a new biomarker panel (and algorithm) to diagnose AD through a combination of degenerative and inflammatory markers, and accelerate the target identification of future therapeutics aimed at modulating the immune system in AD.

摘要